Tools to Measure Noncognitive Symptoms in Nursing Home Residents With Advanced Dementia: A Scoping Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41713492/
Measuring agitation and NCSDs seems feasible in the target population, using CMAI and NPI-Nursing Home version. However, the limited literature does not support robust sample size calculations for interventional studies....
Scoping review identified CMAI and NPI as most used tools for measuring agitation and noncognitive symptoms in advanced dementia nursing home residents, though evidence on validity, responsiveness, and standardization remains limited.
The Highly Selective 5-HT2B Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41677635/
Background: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder and the leading cause of dementia worldwide. Progressive synaptic dysfunction underlies declines in cognition, daily functioning, and the development of neuropsychiatric...
Preclinical study shows selective 5-HT2B receptor antagonist MW073 reduces aggressive behavior in Tg2576 Alzheimer’s mice, implicating serotonin-mediated signaling in neuropsychiatric symptom modulation and therapeutic targeting.
Primary care service utilisation pattern in dementia: a 10-year longitudinal population-based study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41645773/
Person-centred care pathways should anticipate subtype-specific and individual patterns, providing targeted support for those with reduced pre-diagnosis contact who may have unmet needs, while considering early intervention for groups anticipated...
Longitudinal population-based study shows agitation before dementia diagnosis associates with reduced primary care contact in Alzheimer’s disease, suggesting unmet needs and highlighting importance of proactive, person-centred management of behavioral symptoms.
The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41608471/
The endocannabinoid system comprises cannabinoid receptors (CBRs) 1 & 2, endocannabinoids (eCBs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and the enzymes that regulate their production and degradation. ECS plays a significant...
This review examines evidence linking endocannabinoid system dysregulation to neuropsychiatric symptoms in Alzheimer’s disease, highlighting mechanistic and therapeutic implications for managing agitation, anxiety, psychosis, and behavioral disturbances.
Long-Term Effect of Acetylcholinesterase Inhibitors on Behavioral and Psychological Symptoms of Dementia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41569242/
Our study supports the potential role for AChEI in BPSD management, demonstrating a trend toward symptoms stabilization or improvement in patients with mild-moderate dementia. Although the effects were not uniform...
Propensity-matched longitudinal study shows long-term acetylcholinesterase inhibitor use associates with stabilization or improvement of key behavioral and psychological symptoms of dementia, including agitation and irritability, in mild to moderate disease.